GFAP and neoplasm: Soluble GFAP has been previously described to be elevated in the plasma of GBM patients (Jung et al., 2007; Kiviniemi et al., 2015) and possibly applicable in a clinical setting with a sensitivity of 86% and 85% for these high-grade tumours.